News for Castle Biosciences Inc Stock (CSTL)

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research • 02/28/24

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Business Wire • 02/28/24

Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics

Zacks Investment Research • 02/26/24

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Business Wire • 02/26/24

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Business Wire • 02/07/24

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Business Wire • 01/18/24

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

Business Wire • 01/14/24

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Business Wire • 01/08/24

How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%

Zacks Investment Research • 12/12/23

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

Business Wire • 12/01/23

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Business Wire • 11/14/23

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

Business Wire • 11/13/23

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

Business Wire • 11/08/23

Castle Biosciences to Present at Upcoming Investor Conferences

Business Wire • 11/08/23

Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/03/23

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Business Wire • 11/03/23

Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings

Zacks Investment Research • 11/03/23

Early Discovery Data Shows Ability of Castle Biosciences' Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Business Wire • 11/02/23

Castle Biosciences Reports Third Quarter 2023 Results

Business Wire • 11/02/23

Castle Biosciences to Present New Data on its TissueCypher® Barrett's Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Business Wire • 10/24/23

Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2

Business Wire • 10/19/23

New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®

Business Wire • 10/18/23

DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

Business Wire • 10/05/23

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Business Wire • 10/03/23

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Business Wire • 10/02/23